Chemical Structure (1086a7b4 B89b 4bee 8120 5f752626c046 01)
Plavix
Product Images NDC 21695-665
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 21695-665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (1086a7b4 B89b 4bee 8120 5f752626c046 02)
This is a table that presents the Cumulative Event Rate (%) of Cardiovascular Death, Myocardial Infarction, and Stroke for patients taking either Placebo or Plavix in combination with Aspirin. The data is presented graphically with a line graph that shows the difference in event rates over a 12 month follow-up period. The results indicate that Plavix + Aspirin significantly reduces the risk of cardiovascular events compared to placebo + Aspirin. Other standard therapies were also used.*
Figure (1086a7b4 B89b 4bee 8120 5f752626c046 03)
This appears to be a table showing various patient characteristics and the effects of Plavix and placebo in certain treatment scenarios. The table includes information on the number of patients in each scenario and whether Plavix or placebo was better. It also includes information on patient demographics and co-existing medical conditions. The table appears to be showing hazard ratios for different treatment scenarios plotted against time.*
Figure (1086a7b4 B89b 4bee 8120 5f752626c046 04)
This appears to be a portion of a medical study report that compares the number of deaths between a placebo group and a group taking Clopidogrel. The study found that the group taking Clopidogrel had a 7% reduction in risk of death compared to the placebo group, with a p-value of 0.03. The data is also presented visually in a chart, showing the number of deaths per day since the start of the study, up to 28 days.*
Figure (1086a7b4 B89b 4bee 8120 5f752626c046 05)
This text appears to be a statistical analysis of a clinical trial comparing the effectiveness of a placebo to a medication called Tiopldogrel in reducing the risk of an event (not specified). The data shows that out of 2310 patients who received a placebo, 10 experienced an event, while out of 2121 patients who received Tiopldogrel, 9 experienced an event. The results suggest a 9% risk reduction with Tiopldogrel, with a significant p value of 0.002. The timeline shows the number of days since randomization, up to a maximum of 28 days. However, it is not clear what kind of event is being referred to, nor can any further information be gleaned from this text.*
Figure (1086a7b4 B89b 4bee 8120 5f752626c046 06)
Figure (1086a7b4 B89b 4bee 8120 5f752626c046 07)
This appears to be a table of data related to an experimental study with a treatment group (clopidogrel) and a control group (placebo). The data includes the number of participants in each group, their Killip class and previous MI status, as well as the location of their infarct. It also includes statistical analyses such as odds ratio, heterogeneity and a confidence interval. Without more context or explanation, it is difficult to determine the specific implications of this data.*
Figure (1086a7b4 B89b 4bee 8120 5f752626c046 08)
Plavix 75 mg (1086a7b4 B89b 4bee 8120 5f752626c046 09)
This is a description of a medication labeled 5537 5533 (product ID: RP066590). It is a tablet containing 97.875mg of Clopidogrel Bisulfate equivalent to 75mg of Clopidogrel base. The tablet is pink, round, biconvex and film-coated, and it is debossed with "75" on one side and "1171" on the other. This medication is manufactured by Bristol-Myers Squibb/ Sanofi Pharmaceuticals Partnership, Bridgewater, NJ 08807, and it is distributed in Veheuruators, CA 913 VT. The medication should be kept between 59°F-86°F and out of the reach of children.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
